VSTM Verastem, Inc.
Verastem, Inc. (VSTM) is expected to report earnings on November 5, 2026, after the market close. The consensus earnings estimate is a loss of $0.44 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -1.1% since its last earnings release on August 6, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Verastem, Inc.
Verastem Inc is a biopharmaceutical company engaged in discovering and developing proprietary small molecule drugs targeting cancer stem cells along with proprietary companion diagnostics.
Sector
Healthcare
Industry
Biotechnology